Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Nuclear Medicine|November 13, 2015
Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested ProtocolWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|January 22, 2015
Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapiesWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|January 22, 2015
Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRTWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|October 9, 2015
Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG TherapiesWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|February 13, 2015
Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRTWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|February 13, 2015
Incidental Acinic Cell Carcinoma of the Parotid Gland Discordant on 123I-MIBG, 111In-Octreotide, and 18F-FDG PET/CT in a Patient With Neuroendocrine Tumor of the CecumWilliam Makis, Karey McCann, Alexander J B McEwan
Nuclear Medicine and Molecular Imaging|August 18, 2015
The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment ProtocolsWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|February 13, 2015
Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two casesWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|March 19, 2015
Thymoma treated with 177Lu DOTATATE induction and maintenance PRRTWilliam Makis, Karey McCann, Alexander J B McEwan
Clinical Nuclear Medicine|September 12, 2015
Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapyWilliam Makis, Karey McCann, Mark Bryanton, et al.
Pageof 2